A phase Ⅱ, single-arm, exploratory study of GEMOX regimen combined with tislelizumab and donafenib in the perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma with high risk of recurrence

开始日期2025-12-01

申办/合作机构

湖南省人民医院（湖南师范大学附属第一医院）

[+2]

NCT07176754

/ Not yet recruitingN/AIIT

TNF-a Antagonists Attenuate the Systemic Inflammatory Response in Post-cardiac Arrest Syndrome: a Multi Centre, Double-blind, Randomised Controlled Clinical Study

The investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the role of this treatment in modulating the systemic inflammatory response and its potential impact on 90- and 180-day morbidity and mortality and neurological outcomes.

开始日期2025-10-01

申办/合作机构

北京大学第三医院（北京大学第三临床医学院）

[+10]

NCT07209787

/ Recruiting临床4期IIT

A Prospective, Multicenter, Randomized Controlled Study Comparing Effect of Conventional Versus SIS-Reinforced Rectum Anastomosis On Anastomotic Leak Following Radical Resection of Mid-to-Low Rectal Cancer（SISReal）

The goal of this clinical trial is to learn whether using a reinforcing material called SIS (small intestinal submucosa) during bowel connection after rectal cancer surgery can help prevent anastomotic leakage-a serious complication where the connection between two parts of the intestine fails to heal properly. This study will focus on patients with mid-to-low rectal cancer who are scheduled for surgery.
The main questions the study aims to answer are:
Does using an SIS-reinforced connection reduce the rate of anastomotic leakage within 30 days after surgery compared to standard connection methods?
Does it also reduce the need for a temporary stoma (an opening in the abdomen for waste removal)?
Researchers will compare two groups:
Intervention group: Patients who receive the SIS-reinforced connection during surgery.
Control group: Patients who receive the standard connection without reinforcement.
Participants in this study will:
Be randomly assigned to either the intervention or control group.
Undergo standard laparoscopic or robot-assisted rectal cancer surgery.
Be followed up at 30 days, 90 days, and 12 months after surgery to check for complications, stoma status, and quality of life.
This study is being conducted across multiple hospitals in China to ensure the results are reliable and widely applicable.

开始日期2025-09-08

申办/合作机构

北京朝阳医院

[+25]

100 项与湖南省人民医院（湖南师范大学附属第一医院）相关的临床结果

登录后查看更多信息

0 项与湖南省人民医院（湖南师范大学附属第一医院）相关的专利（医药）

登录后查看更多信息

1,661

项与湖南省人民医院（湖南师范大学附属第一医院）相关的文献（医药）

2026-02-01·BIOMATERIALS

Multimodal cascade-amplified phototheranostics for enhanced anti-tumor immunity

Article

作者: Liu, Li ; Huang, Jierou ; Diao, Qingxu ; Zhao, Shaojing ; Yi, Jianing ; He, Xinchun ; Tong, Ming ; Zeng, Jie ; Chen, Haiou ; Lan, Minhuan ; Chen, Liang

Effective immuno-photodynamic therapy (IPDT) is impeded by the limitations of monotherapy approaches, inadequate immune activation, and an immunosuppressive tumor microenvironment (TME). Here, we present a multifunctional phototheranostic nanoplatform based on an A-D-A type photovoltaic molecule (ITCC), which self-assembles into water-soluble nanoparticles (ITCC NPs) via DSPE-PEG-NH₂-2000. Upon near-infrared (NIR) irradiation, ITCC NPs generate reactive oxygen species (ROS) and heat, enabling synergistic photodynamic therapy (PDT) and photothermal therapy (PTT), thereby sequentially triggering immunogenic cell death (ICD), activating the cGAS-STING pathway, and promoting vascular normalization. These cascade effects collectively promote dendritic cells (DCs), natural killer (NK) and T cell activation and infiltration, suppress regulatory T (Treg) cells, and reprogram both systemic and tumor immune microenvironments. Co-administration of the immune checkpoint inhibitor anti-TIGIT (aTIGIT), targeting phototherapy-induced exhausted TIGIT⁺ NK cells, further potentiates antitumor efficacy. Metabolomic analysis reveals ITCC NP-induced reprogramming of tyrosine and lipid metabolism, potentially relieving immunosuppressive metabolic stress and enhancing antitumor immunity. In summary, ITCC NPs function as a single-component, NIR-activated nanoplatform that elicits synergistic phototherapeutic and immunomodulatory effects for cascade amplification of antitumor immunity. Their therapeutic potential is also validated in human hepatocellular carcinoma and breast cancer organoid models.

2026-01-01·JOURNAL OF AFFECTIVE DISORDERS

Gut microbiota, immune cells, and postpartum depression: A mediation Mendelian randomization study

Article

作者: Zhou, Bo ; Li, Mou ; Guo, Jingcheng ; Huang, Xiaoling ; Peng, Xuanxuan

BACKGROUND:

Recent studies suggest links between the gut microbiome, immune cells, and postpartum depression (PPD), but causal relationships are unclear. This study employed the Mendelian randomization (MR) to explore the causal relationship and mediating effect among the three factors.

METHODS:

Summary data from genome-wide association studies were analyzed using MR techniques, including inverse variance weighted, weighted median, MR-Egger, simple mode, and weighted mode. Mediation analysis was conducted to assess the roles of immune cells and gut microbiota in PPD. Sensitivity tests were performed to verify the stability of the findings.

RESULTS:

The analysis results showed that there were 26 positive correlations (risk factors) (OR > 1, p < 0.05) and 19 negative correlations (protective factors) (OR < 1, p < 0.05) between immune cell traits and PPD. In addition, there were 13 positive correlations (OR > 1, p < 0.05) and 20 negative correlations (OR < 1, p < 0.05) between gut microbiota and PPD. Additionally, 6 relationships were identified with the gut microbiota serving as mediators, among them, "GCA-900066755" increased the risk of PPD via "CD45RA^- CD4⁺ T cell %T cell" (9.4 %). With immune cells acting as mediators, "CD4⁺ CD8^dim T cell Absolute Count" was found to reduce the risk of "Holdemania sp900120005" on PPD (25.8 %). Sensitivity tests corroborated the reliability of the findings.

CONCLUSION:

This MR study indicates a causal relationship among immune cells, gut microbiota, and PPD. It clarifies the mediating roles of immune cells and gut microbiota in PPD, offering new insights into the underlying mechanisms for PPD.

2025-12-31·ANNALS OF MEDICINE

Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection

Article

作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Liu, Silan ; Huang, Han ; Chen, Min

BACKGROUND:

Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.

METHODS:

A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.

RESULTS:

Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.

CONCLUSION:

Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.

项与湖南省人民医院（湖南师范大学附属第一医院）相关的新闻（医药）

2025-11-12

·蕊之家

微小病变肾病/局灶节段性肾小球硬化患者招募丨BAT4406F 注射液临床研究

一项评价 BAT4406F 注射液在微小病变肾病/局灶节段性肾小球硬化患者中的有效性和安全性的 II/III 期临床研究主要入选标准 1.年龄18~75岁的成人患者(包含临界值)。 2.临床诊断为NS，且在筛选前5年内通过肾穿刺活检明确病理类型为 MCD/FSGS。 3.筛选前4周(MCD)/6 周(FSGS) 内疾病处于活动/复发状态(尿蛋白定量≥3.5g/d 或连续两天首次晨尿的尿蛋白肌酐比值 [uPCR]均值≥3.5g/g)； 4.使用激素/足量激素(足量激素：泼尼松1mg/kg/d，最大80mg/d，或相应剂量的其他类型激素)治疗4周(MCD) /6 周 (FSGS) 内可达到完全缓解(24h尿蛋白定量<0.3g/d)。主要排除标准 1.继发性 NS (如狼疮性肾炎等)； 2.存在NS相关的遗传缺陷。 3.筛选前6个月内接受过任何B细胞耗竭/B细胞修饰剂治疗(包括但不限于利妥昔单抗、奥妥珠单抗、贝利木单抗、硼替佐米)或其他生物制剂。 4.筛选时外周血 CD19*B淋巴细胞计数低于正常值下限； 5.筛选时外周血 CD4+T 细胞计数<200/puL； 6.对单克隆抗体有过敏史；或过敏体质 7.筛选前60天内接受过免疫抑制剂治疗，例如环磷酰胺、吗替麦考酚酯、环孢素、他克莫司、来氟米特、雷公藤及相关制剂等。 8.筛选前90天或药物的5个半衰期内(以较长时限为准)曾参加过其他试验药物的临床研究，或计划在研究期间参加其他药物的临床试验。 9.肝、肾功能、骨髓储备异常 10.乙肝表面抗原(HBsAg) 阳性 11.5年内有活动性结核，或筛选时存在活动性 TB 的体征或症状。 12.存在任何活动性感染、持续性或慢性感染疾病或有严重感染史； 13.合并有恶性肿瘤病史和自身免疫性疾病。 14.筛选前6个月内有药物、酒精滥用史或筛选前4周内有活疫苗接种或重大手术。参研中心中心名称主要研究者省市北京大学第一医院赵明辉北京市广西医科大学第二附属医院黎伟广西壮族自治区南宁市上海市第一人民医院范秋灵上海市西安交通大学医学院第一附属医院路万虹陕西省西安市中南大学湘雅二医院刘虹湖南省长沙市吉林大学第二医院罗萍吉林省长春市山东第一医科大学第一附属医院（山东省千佛山医院）李文斌山东省济宁市湖南省人民医院陈愔音湖南省长沙市安徽省立医院陈薇安徽省合肥市南昌大学第一附属医院鄢艳江西省南昌市上海交通大学医学院附属瑞金医院谢静远上海市宁夏医科大学总医院田娜宁夏回族自治区银川市中南大学湘雅医院许辉湖南省长沙市郑州人民医院王延辉河南省郑州市厦门大学附属中山医院徐波福建省厦门市南阳市中心医院任东升河南省南阳市浙江大学医学院附属第一医院韩飞浙江省杭州市贵州省人民医院查艳贵州省贵阳市武汉大学人民医院陈铖湖北省武汉市广西医科大学第一附属医院杨桢华广西壮族自治区南宁市北京大学深圳医院陈丽广东省深圳市汕头大学医学院第二附属医院周添标广东省汕头市河北医科大学第二医院李绍梅河北省石家庄市四川省人民医院王芳四川省成都市郑州大学第一附属医院赵占正河南省郑州市联系方式如您自愿同意允许招募团队预留您的姓名缩写及联系方式：欢迎患者将项目编号【013285】、个人姓名、联系方式、所在城市及病史信息发送至我们的招募邮箱 recruitment@smo-clinplus.com 将相关信息回复至微信订阅号 “蕊之家” 详情可咨询我司患者招募服务热线 400 018 9128 （电话咨询请务必告知项目编号：013285项目）

临床2期临床1期疫苗免疫疗法临床申请

2025-11-07

·医药代表

大三甲医院副院长出轨眼科主任，卫健委回应：情况基本属实

这个坊间传闻实锤了。 11 月 6 日，湖南卫健委发布《情况通报》，近日，网传省人民医院祖某某、曾某生活作风问题，经核查，情况基本属实。目前，已对涉事人员暂停职务进行调查，将依规依纪严肃处理。据媒体此前报道，近日，有网友反映，湖南省人民医院一位男性副院长与该院眼科女性副主任存在不正当关系，质疑存在权色交易，并有疑似工作时间在值班室发生关系的不雅视频流出，长达 17 分钟，迅速在社交网络出圈，引发广泛关注。湖南省人民医院官网显示，该副院长系主任医师、教授、博导及博士后合作导师，现任该院副院长，并在门诊科室接诊。涉事女子系眼科副主任，博士，主任医师，副教授，硕士研究生导师。当天，湖南省人民医院宣传办工作人员回应澎湃新闻，目前二人均处于停职状态，医院对此事高度重视，将会有处理结果。对于二人的婚姻状态和视频流出原因，该工作人员表示无法告知。综合自：湖南卫健委、大风新闻、澎湃新闻。相关阅读：四赴进博会，安进来了！官宣！又有两款原研药交给国内药企第十一批国采拟中选结果一览费森尤斯卡比全国热招中跨国药企CEO压货被查！官宣辞职第四批国家鼓励仿制药品目录发布这位药企老板，登顶中国女首富！不受集采影响！新品全国招代理爆料！罗氏要放大招了 2025医保国谈，开始啦！一药企总裁被查，已刑事拘留一外企产品被停采，取消国采中选资格 15人名单公示，违规插手药械采购 DTC销售升温，多家跨国药企加速布局 205个化药，启动带量采购医保局：这类科室是重点，严打超量开药全球大咖齐聚上海！这场肺癌盛会看点拉满 316个品种！新一轮全国药品集采启动全球首个，KYGEVVI®正式获FDA批准 2025医保国谈结束！知名药企高管，被罚500万又一知名外企品种，国内药企接手推广诺华派威妥®来了！诺华公司亮相第八届进博会进博首日，阿斯利康打出“三大组合拳” 外企高管变动：AZ、辉瑞、盈纬达、诺华八赴进博会，来看拜耳今年秀什么 DEE破局，需要这三样东西！灵北在进博会全说了诺和诺德“轻盈小屋”亮相进博会大咪在现场！罗氏C位开馆，这波首秀太炸了！刚刚！第11批国采选省结果发布最新药企内部招聘（11月7日更新）医药代表伴您成长！

高管变更带量采购

2025-11-06

·医脉通

网传三甲医院副院长出轨眼科主任，省卫健委通报：情况基本属实 | 医脉3分钟

今天的医疗圈发生了哪些与你有关的大事？更新、更全的医学动态 3分钟一网打尽 ******** 今日关键词：人工智能+医疗卫生，新版基药目录将公布，超量开药智能监管来源 | 医脉通作者 | 晚报君新闻60秒 ➤五部门联合发文：我国全面推进“人工智能+医疗卫生”应用发展 @国家卫健委 2025年11月4日，国家卫生健康委联合四部门发布《关于促进和规范“人工智能+医疗卫生”应用发展的实施意见》，明确到2027年建立一批卫生健康行业高质量数据集和可信数据空间，形成一批临床专病专科垂直大模型和智能体应用；到2030年，基层诊疗智能辅助应用基本实现全覆盖，推动实现二级以上医院普遍开展医学影像智能辅助诊断、临床诊疗智能辅助决策等人工智能技术应用，“人工智能+医疗卫生”应用标准规范体系基本完善，建成一批全球领先的科技创新和人才培养基地。 ➤超量购药、倒卖牟利5起个人骗取医保基金典型案例公布 @国家医保局 11月5日，国家医保局发布第三期共5起个人骗取医保基金典型案例。其中指出，部分参保人利用门诊特殊疾病待遇、虚构用药需求、跨机构超量购药等手段，甚至勾结“药贩子”、医护人员形成团伙，将医保药品变为牟利工具，严重侵蚀基金安全、破坏医保秩序。鉴于此，医保部门联合司法机关对相关违法违规人员进行了严肃处理，对骗保人员依法刑事处罚、追赃挽损，对违规医护记分、暂停支付资格，彰显对骗保“零容忍”态度。 ➤三甲医院副院长出轨眼科主任？省卫健委通报：情况基本属实 @湖南省卫健委、公开信息 11月6日，湖南省卫健委发布通报称：网传省人民医院祖某某、曾某生活作风问题。经核查，情况基本属实。目前，已对涉事人员暂停职务进行调查，将依规依纪严肃处理。此前，有网友爆料，湖南省人民医院一位男性副院长（祖某某）与该院某门诊科室女性副主任（曾某）存在不正当关系，质疑存在权色交易，并有疑似工作时间在值班室发生关系的不雅视频流出，在多个网络平台被曝光，引发广泛关注。公开资料显示，祖某某现任湖南省人民医院党委委员、副院长，曾某现任湖南省人民医院眼科副主任。医药60秒 ➤新版基本医保药品目录拟于12月发布 @国家医保局近日，国家医保局发文表示，10月30日-11月3日，国家医保局组织开展2025年国家基本医保药品目录谈判竞价和商保创新药目录价格协商工作，120家内外资企业现场参与，其中参与基本医保药品目录谈判竞价的目录外药品127个，参与商保创新药目录价格协商的药品24个。新版基本医保药品目录及首版商保创新药目录拟于12月第一个周末在广州线上线下同步发布，明年1月1日起正式实施。 ➤国家医保局：进一步加强超量开药智能监管 @国家医保局近日，国家医保局印发《关于进一步加强超量开药智能监管工作的通知》，其中提出，依托全国统一医保信息平台，建立健全超量开药问题智能监管筛查预警规则，推动监管关口前移，构建更加严密有力的医保基金智能监管体系。通知明确，监管将紧盯三方面重点：一是重点医保药品，包括查处违法违规案件中频繁涉及的、统筹基金支付金额高且异常增长的、倒卖需求和获利空间大的药品；二是重点异常行为，如无正当理由超量购药、短时间跨机构重复购药、频繁或冒名购药等；三是重点机构和人员，涵盖涉嫌超量开药转卖药品的参保人员、超量开药集中的定点医药机构及科室、涉嫌协助诱导违规开药的医务人员。 ➤新冠病毒感染治疗药物奥格特韦钠胶囊上市 @国家药品监督管理局近日，国家药监局附条件批准浙江艾森药业有限公司申报的1类创新药奥格特韦钠胶囊上市。该药品为口服小分子新冠病毒感染治疗药物，用于治疗轻中型新型冠状病毒感染（COVID-19）的成年患者。国家药监局要求上市许可持有人继续开展相关研究工作，限期完成附条件的要求，及时提交后续研究结果。国际60秒 ➤日本流感病例数连增十周，超千所学校停课 @央视财经近期，日本流感患者迅速增多，以东京为首的日本首都圈多地发布“流感注意警报”。日本厚生劳动省最新公布的数据显示，10月20日到26日的一周内，日本全国定点医疗机构报告流感病例数24276例，增至前一周的约2倍，连续十周增加。单周病例数突破2万例的时间比去年提早了约1个月。不仅是首都圈，日本多地都出现了流感蔓延的趋势，关西地区多地的病例数也增至前一周的2倍至3倍。受流感蔓延影响，日本全国有1015所学校采取了停课等相应措施，这一数量增至前一周的近3倍。责编｜Atai 封面图来源｜医脉通不再单纯追求低价中标！55种药品纳入，第十一批国家组织药品集采开标 | 医脉政事儿男子为了家庭和睦，勉强答应了妻子这个要求！结果一家三口被送入急诊丨医起推理吧医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。 ☟戳这里，更有料！

高管变更带量采购

100 项与湖南省人民医院（湖南师范大学附属第一医院）相关的药物交易

登录后查看更多信息

100 项与湖南省人民医院（湖南师范大学附属第一医院）相关的转化医学

登录后查看更多信息